FILTER
FILTERED INTERVIEW RESULTS
Hui Hui Kiw
VP ASIA, MACDERMID ENTHONE INDUSTRIAL SOLUTIONS
"Companies across China are transferring segments of their business to Thailand, a top choice among Chinese automakers and component manufacturers, with Vietnam, the Philippines, and Indonesia gaining new investments as well."
François Fevrier
CEO, SUEZ ASIA
"We are following closely the evolution of sustainability policies in the region, as more governments become more aware of sustainability imperatives."
Michael Zahra
FORMER PRESIDENT & CEO, DRONE DELIVERY CANADA
"Remote projects may prefer to isolate and limit the number of external individuals visiting as a precaution to avoid the virus spreading, but they need to maintain their supply chain so drones are a perfect unmanned logistics solution."
Wu Yifang
CEO, FOSUN PHARMA
Fosun Pharma is a leading pharma company in China with innovative and global ambitions.
Dr. Jim Li
CEO, SUNDIA
Sundia is a CRO based in China and speaks to GBR of the evolution of the drug discovery process in China.
Dr. Xu Jia
CONSULTING LEADER, PWC CHINA HEALTHCARE AND PHARMACEUTICALS
PwC in China is benefitting from the rise of the biopharma and a flurry of IPO and acquisition activities in the pharma industry more generally.
Jay Dong
GENERAL MANAGER and GLOBAL VP, CST CHINA
CST is expanding its footprint across China where R&D and innovation spending is on the rise.
Jonathan Zhu
PARTNER PRACTICE LEADER, CHINA LIFE SCIENCE & GOVERNMENT AFFAIRS, HEIDRICK & STRUGGLES
H&S is one of the top five recruiting firms globally and is expanding its services in China’s rapidly growing life science sector.
Dr. Wu Xiaobing
COUNTRY MANAGER, PFIZER CHINA & REGIONAL PRESIDENT, PFIZER ESSENTIAL HEALTH GREATER CHINA
Pfizer speaks to GBR about its operations in China.
Ningling Wang
MANAGING PARTNER, FINNEGAN
Finnegan in Shanghai helps Chinese companies protect and enforce their IP in the US and also helps foreign clients with patent litigation in China.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
